Wall Street Zen downgraded Cabaletta Bio Inc. (NASDAQ:CABA) from sell to strong sell on Saturday, September 12, 2026. The research note indicates the firm expects significant downside potential for the stock.
The company’s stock opened at $2.73. Shares are currently trading below their 50-day and 200-day moving averages. This technical position suggests bearish momentum preceded the downgrade.
MarketBeat reports a conflicting consensus Moderate Buy rating for the firm. Analysts maintain an average price target of $15.33 for the stock.
Cabaletta Bio operates as a clinical-stage biotechnology company. The firm develops T cell therapies specifically for autoimmune diseases.